Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PER-001 Intravitreal Implant in Open-Angle Glaucoma
NCT05822245Phase 2Completed
- Sponsor
- Perfuse Therapeutics
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Polymer-based Nanoparticles, Implantable Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of endonentan in open-angle glaucoma (OAG), sponsored by Perfuse Therapeutics. Started May 2023; status: completed.
02
Drugs
endonentan
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT05822245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822245.